Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The metabolic defects of nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes mellitus (T2DM) seem to be specifically targeted by pioglitazone. However, information about its long-term use in this population is limited. OBJECTIVE: To determine the efficacy and safety of long-term pioglitazone treatment in patients with NASH and prediabetes or T2DM. DESIGN: Randomized, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT00994682). SETTING: University hospital. PARTICIPANTS: Patients (n = 101) with prediabetes or T2DM and biopsy-proven NASH were recruited from the general population and outpatient clinics. INTERVENTION: All patients were prescribed a hypocaloric diet (500-kcal/d deficit from weight-maintaining caloric intake) and then randomly assigned to pioglitazone, 45 mg/d, or placebo for 18 months, followed by an 18-month open-label phase with pioglitazone treatment. MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. Secondary outcomes included other histologic outcomes, hepatic triglyceride content measured by magnetic resonance and proton spectroscopy, and metabolic parameters. RESULTS: Among patients randomly assigned to pioglitazone, 58% achieved the primary outcome (treatment difference, 41 percentage points [95% CI, 23 to 59 percentage points]) and 51% had resolution of NASH (treatment difference, 32 percentage points [CI, 13 to 51 percentage points]) (P < 0.001 for each). Pioglitazone treatment also was associated with improvement in individual histologic scores, including the fibrosis score (treatment difference, -0.5 [CI, -0.9 to 0.0]; P = 0.039); reduced hepatic triglyceride content from 19% to 7% (treatment difference, -7 percentage points [CI, -10 to -4 percentage points]; P < 0.001); and improved adipose tissue, hepatic, and muscle insulin sensitivity (P < 0.001 vs. placebo for all). All 18-month metabolic and histologic improvements persisted over 36 months of therapy. The overall rate of adverse events did not differ between groups, although weight gain was greater with pioglitazone (2.5 kg vs. placebo). LIMITATION: Single-center study. CONCLUSION: Long-term pioglitazone treatment is safe and effective in patients with prediabetes or T2DM and NASH. PRIMARY FUNDING SOURCE: Burroughs Wellcome Fund and American Diabetes Association.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Benefi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201).”
In the citing paper
“However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196 -198,202,203), and bone fracture (204,205).”
In the citing paper
“weight gain was also significantly higher in the treatment group [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“a randomized controlled trial including 101 patients with either pre‐ or type 2 diabetes found that 51% in the Pioglitazone group (45 mg/day) had resolution of NASH and 58% achieved the primary outcome of the study (reduction of ≥2 NAS points in two histologic categories without worsening of fibrosis), both significantly [37].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
In the citing paper
“Pioglitazone treatment was also associated with a significant improvement in fibrosis score.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Self-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 2×
“5) mg/dL 149 (36) 153 (34) 1 (−18 to 19) LDL cholesterol level 0.”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 3×
“Additional secondary outcomes included the following: 1) fasting plasma glucose, fasting plasma insulin, FFA, hemoglobin A1c, fasting plasma lipid profile, adiponectin, and cytokeratin-18 concentrations; 2) total body fat percentage, measured by DXA; 3) hepatic triglyceride content, measured by magnetic resonance and…”
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“001 Fibrosis ≥1-point improvement, n (%) 13 (25) 20 (39) 14 (−6 to 34) 0.”
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Targher, G., Bertolini, L., Padovani, R., Rodella, S., Tessari, R., Zenari, L., Day, C., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc06-2247 · Cited by 992
Research works printed but not linked: 1
- Bril F, 2015, Diabetes, 64, A337
Cited by
Items 601–700 of 1,001
Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes
Mantovani, A., Targher, G., & Zoppini, G. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.04.010 · Cited by 13
Yang, J. Y., Moon, A. M., Kim, H. H., Pate, V., Barritt, A. S., Crowley, M. J., Buse, J. B., Stürmer, T., & Alexopoulos, A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107706 · Cited by 12
“We chose to compare newer GLDs to TZD since less is known about the liver effects of these newer agents, whereas TZD have wellestablished benefits in NAFLD; including resolution of non-alcoholic steatohepatitis and improvement in fibrosis.(8,21,22) GLP1RA and SGLT2i are associated with weight loss and preliminary evid…”
MethodHuang, Q., Fang, Q., & Hu, Z. (2020) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2020-0020 · Cited by 15
Kamolvisit, S., Chirnaksorn, S., Nimitphong, H., & Sungkanuparph, S. (2021) · Cureus · doi:10.7759/cureus.19046 · Cited by 16
“Several trials among HIV-uninfected persons with non-alcoholic steatohepatitis demonstrated an improvement in liver fibrosis [14-16].”
BackgroundEbihara, C., Aizawa‐Abe, M., Zhao, M., Gumbilai, V., & Ebihara, K. (2022) · Scientific Reports · doi:10.1038/s41598-021-04036-7 · Cited by 13
Bril, F., Leiva, E. G., Lomonaco, R., Shrestha, S., Kalavalapalli, S., Gray, M. E., & Cusi, K. J. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.08 · Cited by 13
Self-citationComparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis
Jin, D., Cui, Z., Jin, S., Zhou, T., Guo, B., Gao, P., & Li, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1096064 · Cited by 13
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 13
Im, N. N., Koyagura, N., Patil Ashok, M., Jamadar, M. G., & Kumar, V. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/28418.10193 · Cited by 15
Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis
Wegermann, K., Diehl, A. M., & Moylan, C. A. (2018) · Clinical Liver Disease · doi:10.1002/cld.709 · Cited by 16
Pharmacologic Management of Nonalcoholic Steatohepatitis.
Neuschwander‐Tetri, B. A. (2018) · Europe PMC (PubMed Central) · Cited by 14
Non-Alcoholic Fatty Liver Disease
Brůha, R. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.098 · Cited by 12
Population Management of Nonalcoholic Fatty Liver Disease.
Puri, P., & Fuchs, M. A. (2019) · Europe PMC (PubMed Central) · Cited by 18
Gurka, M. J., Mack, J. A., Chi, X., & DeBoer, M. D. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15131 · Cited by 14
Kjær, M. B., George, J., Kazankov, K., & Grønbæk, H. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1817740 · Cited by 14
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 13
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Papaetis, G. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220304124756 · Cited by 13
Tay, P. W. L., Ng, C. H., Lin, S. Y., Chin, Y. H., Xiao, J., Lim, W. H., Lim, S. Y., Fu, C. E., Chan, K. E., Quek, J., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002042 · Cited by 12
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Vasques‐Monteiro, I. M. L., Fernandes‐da‐Silva, A., Miranda, C. S., Silva-Veiga, F. M., Daleprane, J. B., & Souza‐Mello, V. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112177 · Cited by 14
Zhang, S., Cui, Z., Zhang, H., Wang, P., Wang, F., & Zhang, J. (2024) · Nutrients · doi:10.3390/nu16142232 · Cited by 13
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. D. (2025) · Diabetology · doi:10.3390/diabetology6040023 · Cited by 15
“Furthermore, these compounds contribute to the restoration of normal adipose tissue biology, resulting in an improvement in hepatic steatosis [54].”
The Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 12
Self-citationGoon, D. E., Rahim, S. A., Sakri, A. H. M., Mazlan, M., Tan, J. K., Aziz, M. A., Noor, N. M., Ibrahim, E., & Kadir, S. H. S. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00454-9 · Cited by 13
Al‐Busafi, S. A., Alwassief, A., Madian, A., Atalla, H., Alboraie, M. A. A., Elbahrawy, A., & Eslam, M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i8.108730 · Cited by 11
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
Ganakumar, V., Halebidu, T., Goroshi, M., & Ghatnatti, V. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071231220779 · Cited by 10
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 11
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD
Colosimo, S., Miller, H., Koutoukidis, D. A., Marjot, T., Tan, G. D., Harman, D. J., Aithal, G. P., Manousou, P., Forlano, R., Parker, R., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111820 · Cited by 11
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Non-alcoholic fatty liver disease and diabetes
Reyes‐García, R., Rozas-Moreno, P., Llamoza-Torres, C. J., & Mezquita‐Raya, P. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.01.006 · Cited by 11
Wang, G., Li, M., Yu, S., Guan, M., Ma, S., Zhong, Z., Guo, Y., Leng, X., & Huang, H. (2022) · Bioscience Reports · doi:10.1042/bsr20212248 · Cited by 10
Bell, D. S. H. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7787732 · Cited by 12
The effects of the voglibose on non-alcoholic fatty liver disease in mice model
Bae, J., Lee, J. Y., Shin, E., Lee, M., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2022) · Scientific Reports · doi:10.1038/s41598-022-15550-7 · Cited by 11
Zou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 12
Alomari, M., Rashid, M. U., Chadalavada, P. N., Ragheb, J. G., Zafar, H., Suarez, Z. K., Khazaaleh, S., Gonzalez, A. J., & Castro, F. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i4.477 · Cited by 13
NASH Drug Development: Seeing the Light at the End of the Tunnel?
Chen, Y. Q. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00058 · Cited by 13
Potential therapeutic medicines for renal fibrosis: Small-molecule compounds and natural products
Yu, X., Yuan, Z., Deng, Q., Xie, L., Yu, D., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106999 · Cited by 10
Evaluation of liver transplant candidates with non-alcoholic steatohepatitis
Esteban, J. P., & Asgharpour, A. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.03.04 · Cited by 11
Lee, C., Seto, W., Ieong, K., Lui, D. T. W., Fong, C. H.-Y., Wan, H. Y., Chow, W.-S., Woo, Y. C., Yuen, M., & Lam, K. S. L. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.887 · Cited by 12
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 12
Chung, G. E., Jeong, S., Cho, E. J., Yoon, J. W., Yoo, J., Cho, Y., Lee, K., Shin, D. W., Kim, Y. J., Yoon, J., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01691-6 · Cited by 13
Amjad, W., Malik, A., Qureshi, W., Dennis, B. B., Mumtaz, M., Haider, R., Jamal, S. M., Jaura, F., & Ahmed, A. (2022) · Gastroenterology Review · doi:10.5114/pg.2021.112365 · Cited by 17
Koo, D.-J., & Lee, W. (2022) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2022.4.e17 · Cited by 9
Current approaches to diagnosing and treating nonalcoholic fatty liver disease
Никонов, Е. Л., & Va, A. (2018) · Russian Journal of Preventive Medicine · doi:10.17116/profmed201831262 · Cited by 24
Gato, S., García‐Fernández, V., Gil‐Gómez, A., Rojas, Á., Montero‐Vallejo, R., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.26 · Cited by 10
NAFLD and cardiovascular disease
Martins, E., & Oliveira, A. B. F. D. (2018) · Porto Biomedical Journal · doi:10.1016/j.pbj.0000000000000002 · Cited by 9
Connelly, M. A., Rivera, J. V., Guyton, J. R., Siddiqui, M. S., & Sanyal, A. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15935 · Cited by 11
Jalili, R., Somi, M. H., Hosseinifard, H., Salehnia, F., Ghojazadeh, M., Makhdami, N., & Shirmohammadi, M. (2020) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2020.065 · Cited by 9
Finotti, M., Romano, M., Auricchio, P., Scopelliti, M., Brizzolari, M., Grossi, U., Piccino, M., Benvenuti, S., Morana, G., Cillo, U., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060499 · Cited by 9
Fujimori, N., Tanaka, N., Kimura, T., Sano, K., Horiuchi, A., Kato, N., Takahashi, Y., Kuribayashi, N., Sugiura, A., Yamazaki, T., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-01018-1 · Cited by 9
A comprehensive approach to type 2 diabetes mellitus – A recommendation document
Reyes‐García, R., Moreno-Pérez, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Martín, J. E.-S., et al. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.10.013 · Cited by 20
Liu, S.-Y., Huang, C., Huang, S., Liao, T., Kuo, N.-R., Yang, Y., Li, T., Liu, C., Hou, M., & Lin, H. (2021) · Cells · doi:10.3390/cells10113044 · Cited by 11
Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation
Schmidt, K., Spann, A., Khan, M. Q., Izzy, M. J., & Watt, K. D. S. (2023) · Transplantation · doi:10.1097/tp.0000000000004875 · Cited by 10
“58 However, this must be balanced with the adverse event profile, including increased risk of heart failure, weight gain, and mineral bone disease.”
Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus
Kolarš, B., Minaković, I., Grabovac, B., Živanović, D., & Mijatović, V. (2024) · Biomedical Papers · doi:10.5507/bp.2024.009 · Cited by 13
Schreiner, A. D., Zhang, J., Moran, W. P., Koch, D., Marsden, J. E., Bays, C., Mauldin, P. D., & Gebregziabher, M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.002 · Cited by 8
Metabolic dysfunction-associated steatotic liver disease in people with HIV
Gattu, A. K., & Fourman, L. T. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000952 · Cited by 11
Hashim, M. M. A., Khan, M. A. M., Ashraf, M. U., Mohsin, S., Zahoor, K., Niazi, J., Khan, A., Muzaffar, S., Makhdumi, M., Ibad, O. A., et al. (2025) · Cureus · doi:10.7759/cureus.86963 · Cited by 19
“Insulin sensitizers such as pioglitazone have demonstrated histological improvement in NASH, especially in patients with T2DM, but its use is limited by weight gain and concerns about long-term safety [59,60].”
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Long-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study
Pereira, I. V. A., de Oliveira, A. B. S., Zitelli, P. M., Barbieri, L. A., Cardoso, A. C., Monteiro, M. J. D. S. D., de Oliveira, J. S., Stefano, J. T., Altikes, R. G., Reis, A. L. G., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100737 · Cited by 13
“For instance, studies by Bril et al. (2018) and Cusi et al. (2016) have highlighted the importance of addressing insulin resistance in this population, positioning pioglitazone as a logical therapeutic choice.”
Zhu, J., Chen, Y., Han, Y., & Li, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331303 · Cited by 11
Morawska, A., Frankowski, R., Grabarczyk, M., Kosmalski, M., & Różycka-Kosmalska, M. (2025) · Life · doi:10.3390/life15111713 · Cited by 13
“…T2DM, offering sustained improvements in liver histology and metabolic parameters such as reduced hepatic triglyceride content, improvement in individual histological scores, including the fibrosis score, and upregulation of insulin sensitivity in adipose tissue, liver, and skeletal muscles [103].”
Malandris, K., Charalampidis, K., Loomba, R. S., & Sinakos, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01621-w · Cited by 12
Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes
EINHORN, D. F., & Fonseca, V. A. (2016) · Endocrine Practice · doi:10.4158/ep161409.co · Cited by 8
Mino, M., Kakazu, E., Sano, A., Katsuyama, H., Hakoshima, M., Yanai, H., Aoki, Y., Imamura, M., Yamazoe, T., Mori, T., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13898 · Cited by 11
Mechanisms of Non-alcoholic Fatty Liver Disease and Beneficial Effects of Semaglutide: A Review
Alfawaz, S. A., Burzangi, A. S., & Esmat, A. (2024) · Cureus · doi:10.7759/cureus.67080 · Cited by 16
“Additionally, they facilitate the restoration of typical adipose tissue functions and contribute to the reduction of fat accumulation in the liver [97].”
BackgroundShi, R., Chai, K., Wang, H., Zhou, J., Yang, S., Li, J., Qiao, C., Sheng, X., Zhang, X., & Wu, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70002 · Cited by 11
Recent advances in understanding/managing type 2 diabetes mellitus
Aschner, P. J. (2017) · F1000Research · doi:10.12688/f1000research.11192.1 · Cited by 9
Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease
Iruzubieta, P., González, M., Cabezas, J., Arias-Loste, M. T., & Crespo, J. (2018) · InTech eBooks · doi:10.5772/intechopen.72668 · Cited by 10
Chiglitazar: a novel pan-PPAR agonist
DeFronzo, R. A. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.04.012 · Cited by 8
Polycystic ovary syndrome and nonalcoholic fatty liver disease
Georgescu, C. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823045-9.00007-9 · Cited by 10
Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent
Салухов, В. В., & Анатольевна, К. Е. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-10-10-21 · Cited by 10
Metabolomics of Mice with Type 2 Diabetes and Nonalcoholic Fatty Liver Treated by Acupuncture
Guo, Y., Zhang, L., Li, M., Lin, L., Xue, F., Gao, W., Xu, X., & Huang, H. (2024) · International Journal of Endocrinology · doi:10.1155/2024/5568337 · Cited by 7
Pleural Effusion Due to Use of Pioglitazone: A Case Report
Xue, J., Liu, W., Shi, F., Zheng, J., & Ma, J. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0109 · Cited by 8
Sofyana, N. T., Zheng, J., Manabe, Y., Yamamoto, Y., Kishino, S., Ogawa, J., & Sugawara, T. (2020) · Lipids · doi:10.1002/lipd.12219 · Cited by 9
Horizon scanning of therapeutic modalities for nonalcoholic steatohepatitis
Patikorn, C., Veettil, S. K., Phisalprapa, P., Pham, T. A., Kowdley, K. V., & Chaiyakunapruk, N. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100315 · Cited by 9
Nonalcoholic Fatty Liver Disease
Boyle, M., & Anstee, Q. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch35 · Cited by 8
Khan, M. M., Khan, Z. A., & Khan, M. A. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i6.767 · Cited by 7
Sun, Y., Yuan, X., Hu, Z., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116730 · Cited by 10
Liu, B. D. X., Aly, M., Lin, C. H.-T., Panesar, N., Hill, H., & Qureshi, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.017 · Cited by 10
Banerjee, M., Pal, R., & Pal, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70187 · Cited by 9
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
Machida, T., Obara, T., Miyazaki, M., Inoue, J., & Mano, N. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100699 · Cited by 8
The Burden of Nonalcoholic Steatohepatitis: A Systematic Review of Epidemiology Studies
Tapper, E. B., Fleming, C., Rendon, A., Fernandes, J. D. D. R., Johansen, P., Augusto, M., & Nair, S. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.06.016 · Cited by 10
Li, H., Song, L., Wei, M., Yuan, X., Wu, W., Kaneko, G., Ji, H., & Sun, J. (2023) · Aquaculture Reports · doi:10.1016/j.aqrep.2023.101856 · Cited by 9
Kumar, J., Mohsin, S., Hasan, M., Bilal, A. R., Ali, K. M., Umer, A. M., Hadi, D. Z. M., Nandlal, S., & Kumar, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102261 · Cited by 7
Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study
Suwała, S., Białczyk, A., Koperska, K., Rajewska, A., Krintus, M., & Junik, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247760 · Cited by 8
Park, J.-Y., Lee, J., Choi, Y., Min, K. W., Han, K. A., Ahn, K. J., Lim, S. K., Kim, Y., Ahn, C. W., Choi, K. M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0259 · Cited by 8
Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Nendouvhada, L. P., Sibuyi, N. R. S., Fadaka, A. O., Meyer, S., Madiehe, A. M., Meyer, M., & Gabuza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115571 · Cited by 8
“Although some are effective to some extent, most of these drugs have no effect on liver histology and more clinical trials are still required to prove their safety [40].”
BackgroundInfluentialJia, X., Li, M., Zhang, W., Guo, Y., Xue, F., Ma, S., Yu, S., Zhong, Z., & Huang, H. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01416-7 · Cited by 8
How to Approach a Patient With Nonalcoholic Fatty Liver Disease
Tilg, H. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.016 · Cited by 10
Prevention Strategies for Hepatocellular Carcinoma
Erstad, D. J., Razavi, A. A., Shen, L., Tanabe, K. K., & Fuchs, B. C. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8_13 · Cited by 7
Fructose and Nonalcoholic Fatty Liver Disease
Lustig, R. H. (2016) · Journal of the California Dental Association · doi:10.1080/19424396.2016.12221067 · Cited by 8
Yano, K., Seko, Y., Takahashi, A., Okishio, S., Kataoka, S., Takemura, M., Okuda, K., Mizuno, N., Taketani, H., Umemura, A., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10020086 · Cited by 8
“However, antidiabetic agents, including pioglitazone [9,10] and glucagon-like peptide-1 (GLP-1) agonists [11], are expected to reduce hepatic fat content or hepatic inflammation in NAFLD.”
BackgroundState-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 8
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 8
Maiwall, R., & Gupta, M. (2020) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.10.11 · Cited by 6
Nonalcoholic Fatty Liver Disease
Day, C. P., & Anstee, Q. M. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562941 · Cited by 7
Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH
Leey, J., & Cusi, K. J. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14473 · Cited by 7
Self-citation
Metadata
- Authors
- Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., Webb, A., & Portillo-Sanchez, P.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- From University of Florida and Malcom Randall Veterans Affairs Medical Center, Gainesville, Florida, and University of Texas Health Science Center at San Antonio and Audie L. Murphy Veterans Affairs Medical Center, San Antonio, Texas.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-09-06
- Volume
- 165
- Issue
- 5
- Pages
- 305-315
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2470709274
- Cited by
- 1,024
- References
- 62
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 109 · 2023: 103 · 2022: 116 · 2021: 131 · 2020: 108 · 2019: 85 · 2018: 85 · 2017: 67 · 2016: 27
- FWCI
- 82.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- U.S. Department of Veterans Affairs (1 I01 CX000167-01)
- American Diabetes Association
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- pioglitazone, nonalcoholic steatohepatitis, prediabetes, type 2 diabetes, long-term treatment, hypocaloric diet, NASH resolution, liver fibrosis, hepatic triglyceride content, insulin sensitivity, insulin resistance, PPARγ agonists, drug safety, adverse events, liver histopathology, hepatic steatosis
- MeSH terms
- Pioglitazone, Transaminases, Diabetes Mellitus, Type 2, Diet, Reducing, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Prediabetic State, Triglycerides, Biomarkers, Weight Gain, Thiazolidinediones, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.